Homburger advises ADC Therapeutics SA in its USD 325 m financing agreement with HealthCare Royalty

On August 26, 2021, ADC Therapeutics SA (NYSE: ADCT), a Swiss-based commercial-stage oncology-focused biotechnology company, announced that it had entered into a royalty purchase agreement with HealthCare Royalty. Under the agreement, ADC Therapeutics will receive up to USD 325 m, and HealthCare Royalty will receive a capped royalty interest on ZYNLOTA™ and Cami (camidanlumab tesirine).

Homburger advises ADC Therapeutics SA on the Swiss law and tax aspects of the transaction. The Homburger team is led by partner Daniel Häusermann (Corporate / M&A, Capital Markets) and includes partners Dieter Grünblatt and Reto Heuberger (Tax), Georg Rauber (IP / IT), Benjamin Leisinger (Financing and Investment Products) as well as associates Estelle Piccard (Corporate / M&A, Capital Markets), David Borer and Stefan Bindschedler (both Financing and Investment Products).